ALZAI health

From Passive to Proactive
The Impact Non-Invasive AD Risk Stratification

Find MCI / Mild AD Patients Eligible for Disease-Modifying Drugs

THE PROBLEM


Alzheimer's **patient identification is largely passive**, leading to missed treatment opportunities

- **Diagnosis occurs after disease progression** creates patient complaint
- Clinical workflows are largely **reactive, not predictive**
- **No screening delays treatment eligibility**

Massive U.S. disease burden:

- **7 Million** American with AD
- **10s of Millions** current at-risk or in early stages
- **Up to 80%** of AD patients will be diagnosed too late for intervention

Current patient journey (passive model)



Passive model - patients diagnosed too late for treatment

THE ALZAI SOLUTION

ALZAI enables **proactive identification of Alzheimers patients**


Using routine existing patient data, ALZAI automatically:

- Identifies individuals at **high risk of MCI / Mild AD diagnosis**
- Stratify **high risk individuals by projected year of diagnosis**
- Enables **earlier referral and diagnostic evaluation**
- Prioritizes patients for **efficient use of diagnostic resources**

Impact of the Proactive ALZAI :

- **3X more AD patients identified within the therapeutic window**
- **Major increased eligibility for disease-modifying therapies**
- **More efficient use of clinical and diagnostic pathways**

Enhanced patient journey (proactive model)



Enabling earlier patient identification and treatment access

CLINICAL VALIDATION

Retrospective Multinational Study

- **1.6M+** patient records analyzed
- Data sources: **over 100M** datasets from Clalit Health Services (Israel) and HealthVerity (USA)
- Population: **Diverse populations** from across the USA and Israel
- Outcome: Validation of ALZAI Risk-Screening capability **up to 10 years before diagnosis**

Result:

ALZAI demonstrated robust predictive performance in identifying individuals at elevated risk of Alzheimer's disease in early stages.

At least **3X more patients were identified within the mild-stage disease window** compared to standard of care.

LEADERSHIP TEAM



Hayim Raclaw
Chairperson, Chief Executive Officer & Co-founder



Dr. Amir Glik, MD
Director, Chief Medical Officer & Co-founder



Roy Kait
Director, Chief Revenue Officer & Co-founder



Prof. Chen Hajaj
Head of Data Science & Co-founder

PARTNERS

CLALIT HEALTH

ARIEL UNIVERSITY

healthverity

ABOUT US

ALZAI Health Corp. is a predictive AI healthcare company focused on enabling early detection of under-diagnosed chronic diseases through non-invasive, data-driven risk stratification.
Our platform identifies individuals at elevated risk **before symptoms appear**, enabling proactive intervention at scale.

Key capabilities:

- Leverages existing healthcare data (EHR + labs)
- Identifies patients years before diagnosis
- Enables proactive clinical intervention at scale

CONTACT US

info@alzaihealth.com
+1.416.727.6244
https://www.alzaihealth.com